vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Bristow Group Inc. (VTOL). Click either name above to swap in a different company.
Bristow Group Inc. is the larger business by last-quarter revenue ($377.3M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 4.9%, a 6.2% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 6.7%). Bristow Group Inc. produced more free cash flow last quarter ($47.8M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Bristow Helicopters Limited is a British civil helicopter operator originally based at Aberdeen Airport, Scotland, which is currently a part of the U.S.-based Bristow Group which in turn has its corporate headquarters in Houston, Texas, U.S. In 2020, Bristow Group was merged with Era Helicopters, a large U.S.-based commercial helicopter operator that was previously a division of Era Aviation, with the two companies then continuing to use the Bristow name.
ANIP vs VTOL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $377.3M |
| Net Profit | $27.5M | $18.4M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 8.5% |
| Net Margin | 11.1% | 4.9% |
| Revenue YoY | 29.6% | 6.7% |
| Net Profit YoY | 367.5% | -42.1% |
| EPS (diluted) | $1.14 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $377.3M | ||
| Q3 25 | $227.8M | $386.3M | ||
| Q2 25 | $211.4M | $376.4M | ||
| Q1 25 | $197.1M | $350.5M | ||
| Q4 24 | $190.6M | $353.5M | ||
| Q3 24 | $148.3M | $365.1M | ||
| Q2 24 | $138.0M | $359.7M | ||
| Q1 24 | $137.4M | $337.1M |
| Q4 25 | $27.5M | $18.4M | ||
| Q3 25 | $26.6M | $51.5M | ||
| Q2 25 | $8.5M | $31.7M | ||
| Q1 25 | $15.7M | $27.4M | ||
| Q4 24 | $-10.3M | $31.8M | ||
| Q3 24 | $-24.2M | $28.2M | ||
| Q2 24 | $-2.3M | $28.2M | ||
| Q1 24 | $18.2M | $6.6M |
| Q4 25 | 14.1% | 8.5% | ||
| Q3 25 | 15.9% | 13.1% | ||
| Q2 25 | 6.6% | 11.3% | ||
| Q1 25 | 13.3% | 9.6% | ||
| Q4 24 | -2.3% | 9.0% | ||
| Q3 24 | -13.8% | 9.1% | ||
| Q2 24 | 3.7% | 12.4% | ||
| Q1 24 | 14.8% | 6.8% |
| Q4 25 | 11.1% | 4.9% | ||
| Q3 25 | 11.7% | 13.3% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 7.8% | ||
| Q4 24 | -5.4% | 9.0% | ||
| Q3 24 | -16.3% | 7.7% | ||
| Q2 24 | -1.7% | 7.8% | ||
| Q1 24 | 13.2% | 2.0% |
| Q4 25 | $1.14 | $0.61 | ||
| Q3 25 | $1.13 | $1.72 | ||
| Q2 25 | $0.36 | $1.07 | ||
| Q1 25 | $0.69 | $0.92 | ||
| Q4 24 | $-0.45 | $1.07 | ||
| Q3 24 | $-1.27 | $0.95 | ||
| Q2 24 | $-0.14 | $0.96 | ||
| Q1 24 | $0.82 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $286.2M |
| Total DebtLower is stronger | — | $671.5M |
| Stockholders' EquityBook value | $540.7M | $1.1B |
| Total Assets | $1.4B | $2.3B |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $286.2M | ||
| Q3 25 | $262.6M | $245.5M | ||
| Q2 25 | $217.8M | $251.8M | ||
| Q1 25 | $149.8M | $191.1M | ||
| Q4 24 | $144.9M | $247.5M | ||
| Q3 24 | $145.0M | $200.3M | ||
| Q2 24 | $240.1M | $178.6M | ||
| Q1 24 | $228.6M | $140.6M |
| Q4 25 | — | $671.5M | ||
| Q3 25 | — | $675.0M | ||
| Q2 25 | — | $705.2M | ||
| Q1 25 | — | $701.9M | ||
| Q4 24 | — | $689.8M | ||
| Q3 24 | — | $629.1M | ||
| Q2 24 | — | $594.2M | ||
| Q1 24 | — | $544.1M |
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.0B | ||
| Q2 25 | $436.8M | $984.4M | ||
| Q1 25 | $418.6M | $931.7M | ||
| Q4 24 | $403.7M | $891.7M | ||
| Q3 24 | $405.9M | $899.2M | ||
| Q2 24 | $455.8M | $849.1M | ||
| Q1 24 | $452.0M | $820.7M |
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.3B | $2.3B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $920.8M | $2.0B | ||
| Q1 24 | $914.5M | $1.9B |
| Q4 25 | — | 0.63× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $76.9M |
| Free Cash FlowOCF − Capex | $29.1M | $47.8M |
| FCF MarginFCF / Revenue | 11.8% | 12.7% |
| Capex IntensityCapex / Revenue | 0.5% | 7.7% |
| Cash ConversionOCF / Net Profit | 1.10× | 4.17× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $56.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $76.9M | ||
| Q3 25 | $44.1M | $23.1M | ||
| Q2 25 | $75.8M | $99.0M | ||
| Q1 25 | $35.0M | $-603.0K | ||
| Q4 24 | $15.9M | $51.1M | ||
| Q3 24 | $12.5M | $66.0M | ||
| Q2 24 | $17.4M | $33.7M | ||
| Q1 24 | $18.3M | $26.7M |
| Q4 25 | $29.1M | $47.8M | ||
| Q3 25 | $38.0M | $-6.2M | ||
| Q2 25 | $71.8M | $67.4M | ||
| Q1 25 | $32.5M | $-52.7M | ||
| Q4 24 | $13.5M | $-32.4M | ||
| Q3 24 | $7.7M | $9.0M | ||
| Q2 24 | $13.0M | $-16.7M | ||
| Q1 24 | $13.7M | $-37.9M |
| Q4 25 | 11.8% | 12.7% | ||
| Q3 25 | 16.7% | -1.6% | ||
| Q2 25 | 34.0% | 17.9% | ||
| Q1 25 | 16.5% | -15.0% | ||
| Q4 24 | 7.1% | -9.2% | ||
| Q3 24 | 5.2% | 2.5% | ||
| Q2 24 | 9.4% | -4.6% | ||
| Q1 24 | 10.0% | -11.2% |
| Q4 25 | 0.5% | 7.7% | ||
| Q3 25 | 2.7% | 7.6% | ||
| Q2 25 | 1.9% | 8.4% | ||
| Q1 25 | 1.3% | 14.9% | ||
| Q4 24 | 1.3% | 23.6% | ||
| Q3 24 | 3.2% | 15.6% | ||
| Q2 24 | 3.2% | 14.0% | ||
| Q1 24 | 3.3% | 19.2% |
| Q4 25 | 1.10× | 4.17× | ||
| Q3 25 | 1.66× | 0.45× | ||
| Q2 25 | 8.87× | 3.12× | ||
| Q1 25 | 2.23× | -0.02× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | 2.34× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | 1.00× | 4.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
